Trending...
- Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book - 229
- Salestrics' $1.5 Million SAFE Financing Round Remains Open Following $148,500 Pre-Seed Investment - 143
- Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
MILPITAS, Calif. , June 18, 2025 ~ Galaxy Therapeutics, a leading medical device company specializing in the treatment of brain aneurysms, has announced the appointment of Dr. Michael Alexander as their new Chief Medical Officer. With over two decades of experience in neurosurgery and clinical research, Dr. Alexander brings a wealth of knowledge and expertise to the company.
In his new role, Dr. Alexander will provide global medical leadership for Galaxy's clinical development programs, including the ongoing Saccular Endovascular Aneurysm Lattice (SEAL™) IT IDE trial and future studies focused on treating complex brain aneurysms with the SEAL device. This newly created position highlights Galaxy's commitment to advancing their innovative technology and bringing it to patients worldwide.
Dr. Alexander is a highly distinguished specialist in the field of neurosurgery, with dual training in cerebrovascular surgery and neurointerventional procedures. He has held various leadership positions at prestigious institutions such as Cedars-Sinai Medical Center in Los Angeles, where he currently serves as Professor and Vice Chair of Neurosurgery, Co-Director of the Comprehensive Stroke Center, Director of the Neurovascular Center, and Staff Physician IV (Neurosurgery). He also served as Team Neurosurgeon for the Los Angeles Rams during their 2016-2017 season.
More on The Californer
Prior to joining Cedars-Sinai, Dr. Alexander spent seven years as an Associate Professor at Duke University Medical Center and completed a fellowship at UCLA Medical Center. Despite his new role at Galaxy Therapeutics, he will continue to serve in his current academic and clinical positions.
Dr. Sam Zaidat, President and CEO of Galaxy Therapeutics, expressed his excitement about having Dr. Alexander join their executive team. He praised Dr. Alexander's extensive experience in clinical trials and his stellar reputation within the neurointerventional community.
"Dr. Alexander's unmatched clinical trial experience, scientific rigor, and stellar reputation in the neurointerventional community make him an ideal Chief Medical Officer," said Dr. Zaidat. "As such, we are honored to welcome him to the executive team and are confident that he will be instrumental in helping us bring our technology to patients worldwide."
Dr. Zaidat also mentioned that Galaxy Therapeutics will continue to expand its clinical and scientific leadership team as they work towards advancing their innovative SEAL device, designed to address the most challenging aneurysm anatomies.
More on The Californer
Throughout his career, Dr. Alexander has participated in over 45 clinical trials and has been continuously funded by the National Institutes of Health (NIH) for the past 18 years. He is a Past President of the Society of NeuroInterventional Surgery (SNIS), co-author of two textbooks, and has published over 160 peer-reviewed articles in the field of neurovascular disease.
Dr. Alexander received his medical degree from Georgetown University School of Medicine and completed fellowships in Neurovascular and Skull Base Surgery at Barrow Neurological Institute and NeuroIntervention at David Geffen School of Medicine at UCLA.
With Dr. Alexander's expertise and leadership, Galaxy Therapeutics is poised to make significant strides in their mission to provide innovative treatments for brain aneurysms. As they continue to grow, they remain committed to expanding their team with top talent in order to bring their technology to patients around the world.
In his new role, Dr. Alexander will provide global medical leadership for Galaxy's clinical development programs, including the ongoing Saccular Endovascular Aneurysm Lattice (SEAL™) IT IDE trial and future studies focused on treating complex brain aneurysms with the SEAL device. This newly created position highlights Galaxy's commitment to advancing their innovative technology and bringing it to patients worldwide.
Dr. Alexander is a highly distinguished specialist in the field of neurosurgery, with dual training in cerebrovascular surgery and neurointerventional procedures. He has held various leadership positions at prestigious institutions such as Cedars-Sinai Medical Center in Los Angeles, where he currently serves as Professor and Vice Chair of Neurosurgery, Co-Director of the Comprehensive Stroke Center, Director of the Neurovascular Center, and Staff Physician IV (Neurosurgery). He also served as Team Neurosurgeon for the Los Angeles Rams during their 2016-2017 season.
More on The Californer
- Vehicle theft in California dropped nearly 25% in 2025
- Verbica: As the Pentagon Re-frames Its Rigor, So Too Should America's Schools and Congress
- The largest Guatemalan festival outside of Guatemala! The 10th Annual Festival Chapin Los Angeles
- California: Governor Newsom expands statewide partnerships with additional cities to clean up encampments on highways
- $620 Million in Recent Government Contract Awards with More Than $1.2 Billion in Annualized Revenue: Circle8 Group (N A S D A Q: CIRC)
Prior to joining Cedars-Sinai, Dr. Alexander spent seven years as an Associate Professor at Duke University Medical Center and completed a fellowship at UCLA Medical Center. Despite his new role at Galaxy Therapeutics, he will continue to serve in his current academic and clinical positions.
Dr. Sam Zaidat, President and CEO of Galaxy Therapeutics, expressed his excitement about having Dr. Alexander join their executive team. He praised Dr. Alexander's extensive experience in clinical trials and his stellar reputation within the neurointerventional community.
"Dr. Alexander's unmatched clinical trial experience, scientific rigor, and stellar reputation in the neurointerventional community make him an ideal Chief Medical Officer," said Dr. Zaidat. "As such, we are honored to welcome him to the executive team and are confident that he will be instrumental in helping us bring our technology to patients worldwide."
Dr. Zaidat also mentioned that Galaxy Therapeutics will continue to expand its clinical and scientific leadership team as they work towards advancing their innovative SEAL device, designed to address the most challenging aneurysm anatomies.
More on The Californer
- Lewis County Hydrogen Alliance Launches Phase 1 Work to Turn Forest Residuals into Fuel-Grade Hydrogen and Dispatchable Clean Power
- Next Gen Fibre Selects netElastic vBNG and CGNAT to Fuel Rapid Nationwide Expansion and Eliminate Network Bottlenecks
- From Setback to Strength: Joel Rodriguez-Tirado Reveals the Grit Formula for Unshakable Focus & Exp
- Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
- From California to National Publication: How Impact & Influence Magazine Is Expanding Across America
Throughout his career, Dr. Alexander has participated in over 45 clinical trials and has been continuously funded by the National Institutes of Health (NIH) for the past 18 years. He is a Past President of the Society of NeuroInterventional Surgery (SNIS), co-author of two textbooks, and has published over 160 peer-reviewed articles in the field of neurovascular disease.
Dr. Alexander received his medical degree from Georgetown University School of Medicine and completed fellowships in Neurovascular and Skull Base Surgery at Barrow Neurological Institute and NeuroIntervention at David Geffen School of Medicine at UCLA.
With Dr. Alexander's expertise and leadership, Galaxy Therapeutics is poised to make significant strides in their mission to provide innovative treatments for brain aneurysms. As they continue to grow, they remain committed to expanding their team with top talent in order to bring their technology to patients around the world.
Filed Under: Business
0 Comments
Latest on The Californer
- Crossroads4Hope Announces The Lipschutz Women's Fund
- FixMyReports.com Launches DIY Credit Dispute Platform Putting Consumers in Control
- Why Operators Are Replacing Compliance Spreadsheets With AI Platforms in 2026
- AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
- 91 Per Cent of Enterprises Will Increase AI Spending. Most Can't See the Cost — or the Risk!
- SlickCashLoan Publishes Guide to Loan Reviews Without Traditional Credit Checks
- California secures federal assistance to support response to Dove Fire in Tuolumne County
- Impact LA Celebrates the 7th Annual Kobe Day Back-to-School Backpack Giveaway
- Arkansas Duo Cliff & Susan Return for Seventh Santa Barbara Summer to Headline The Red Piano's 10th Anniversary
- Melospeech Celebrates 5 Years of Service with Local Community Gathering at New Paris Baguette
- Ferrari Enthusiast Jon Robert Quinn Says Ferrari Luce Could Redefine Performance EVs
- Ferrari Challenge at Sonoma Raceway: Race Coverage and Event Highlights
- Hegemonys Clothing Announces Online Store Launch and Premium Streetwear Drop
- New ProEssentials v11: Native WinUI Charting Library, 100M Points in 15ms, Following Microsoft's Vision for True Native Swap-Chain Rendering
- Tropical Storm Genevieve Forms in the Eastern Pacific, Forecast to Rapidly Intensify
- SWENSON Completes Landmark Big Wave Center
- Casino M8trix Expands Community Investment Through AACSA Partnership
- TCN Vending USA Expands with 5 Strategic U.S. Warehouses for Coast-to-Coast Fast Delivery
- Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
- ForityCloud Launches Tandem, a Fully Managed Private Cloud for Businesses Ready to Scale